Thrombocytosis and acquired platelet dysfunction

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Thrombocytosis means a platelet count above the laboratory reference range, commonly at least 450 × 10⁹/L. Most cases are reactive, especially after infection, inflammation, iron deficiency, tissue injury, haemorrhage, malignancy or splenectomy. Persistence, unexplained thrombosis, splenomegaly, constitutional symptoms, erythrocytosis, leucocytosis or abnormal morphology increases concern for a myeloproliferative neoplasm. Repeat the count after acute illness and investigate a plausible driver rather than ordering indiscriminate molecular tests from one result.

Thrombotic and bleeding risk are not linear functions of platelet count. Reactive thrombocytosis rarely needs count-directed therapy. In essential thrombocythaemia and related neoplasms, age, prior thrombosis, JAK2 status, cardiovascular factors and disease phenotype guide prevention. Extreme counts can paradoxically bleed because high-molecular-weight VWF multimers are lost. Therefore aspirin may help platelet-mediated microvascular symptoms in selected clonal disease yet worsen active bleeding or acquired von Willebrand syndrome.

Acquired platelet dysfunction is a functional primary-haemostasis defect. Aspirin irreversibly inhibits platelet cyclo-oxygenase; clopidogrel and related agents block P2Y12 signalling. Uraemic toxins impair adhesion and activation, anaemia reduces platelet margination, and dialysis or extracorporeal circuits can further alter function. Paraproteins, advanced liver disease, cardiopulmonary bypass and some antimicrobials may contribute. Routine PT and APTT can remain normal because they test plasma coagulation rather than platelet plug formation.

Management begins with the cause and the clinical need for haemostasis. Stop or reverse contributory medicines only after weighing the indication and thrombosis risk, particularly after recent coronary stenting. Treat iron deficiency, infection, inflammation and renal failure. Use local pressure, procedural haemostasis and tranexamic acid for suitable mucosal bleeding. Desmopressin can transiently improve uraemic primary haemostasis but has tachyphylaxis and hyponatraemia risk. Platelets, VWF concentrate or urgent cytoreduction are selected by mechanism with haematology and the procedural specialty.

Key points

Confirm genuine thrombocytosis with a repeat FBC and film; the platelet count alone does not distinguish a reactive process from a myeloproliferative neoplasm.
First-line cause assessment includes history, examination, serial counts, ferritin and iron studies, CRP or ESR, renal and liver function and review for infection, inflammation, bleeding, surgery, splenectomy and malignancy.
Persistent unexplained thrombocytosis requires haematology assessment with JAK2 V617F, then CALR and MPL or an appropriate myeloid panel; BCR::ABL1 testing and marrow examination depend on phenotype.
A high count does not automatically require aspirin or cytoreduction: reactive thrombocytosis is treated by correcting the driver, while confirmed clonal disease is managed by age, thrombosis history, mutation and bleeding risk.
Extreme thrombocytosis with bleeding is a warning for acquired von Willebrand syndrome; check VWF activity and antigen and withhold aspirin until haemostasis risk is understood.
Acquired platelet dysfunction can cause bleeding with a normal count, PT and APTT. Diagnose from phenotype, medicine exposure, renal or systemic disease and specialist functional testing when it will change care.
For serious uraemic bleeding or an urgent procedure, correct anaemia and dialysis factors and consider desmopressin 0.3 micrograms/kg intravenously over 20–30 minutes under specialist supervision.
Platelet transfusion is reserved for clinically important bleeding or urgent procedures where expected benefit exceeds thrombosis risk; recent antiplatelet exposure alone is not a universal indication.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Reactive platelet production

Inflammation, infection, tissue damage, malignancy, iron deficiency, bleeding, haemolysis and postsplenectomy physiology raise thrombopoietic signalling without a primary marrow clone.

Clonal myeloid disease

Essential thrombocythaemia, polycythaemia vera, prefibrotic myelofibrosis, chronic myeloid leukaemia and other neoplasms produce autonomous thrombocytosis with distinct vascular implications.

Acquired functional inhibition

Aspirin and P2Y12 inhibitors, uraemic toxins, paraproteins, liver disease, extracorporeal circuits and selected medicines impair adhesion, activation or aggregation independently of count.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Cytokine-driven megakaryopoiesis
Interleukin-6 and thrombopoietin responses accelerate platelet production during inflammation or iron deficiency; the count usually falls when the driver resolves.
2
Clonal activation and thrombosis
JAK-STAT pathway activation in myeloproliferative neoplasms alters platelets, leucocytes and endothelium, creating arterial, venous and microvascular thrombosis not predicted by count alone.
3
Extreme-count VWF loss
Very high platelet mass adsorbs and accelerates cleavage of high-molecular-weight von Willebrand multimers, producing mucocutaneous bleeding despite abundant circulating platelets.
4
Defective primary haemostasis
Uraemia, medicines and paraproteins disturb platelet-vessel-wall interaction, secretion or aggregation, so bleeding time at injured mucosa or surgical surfaces increases while PT may remain normal.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Reactive context

Recent infection, inflammatory flare, operation, haemorrhage or iron deficiency with a parallel CRP or ferritin abnormality favours secondary thrombocytosis.

Clonal clues

Persistent isolated elevation, splenomegaly, aquagenic symptoms, erythromelalgia, leucocytosis or unusual-site thrombosis should prompt an MPN pathway.

Platelet-type bleeding

Epistaxis, gum bleeding, easy bruising, heavy periods and immediate procedural oozing suggest defective primary haemostasis.

Uraemic phenotype

Advanced kidney failure with anaemia, bruising or catheter and operative oozing can reflect dysfunction despite an adequate platelet count.

Count-related paradoxRed flag

Mucosal bleeding at an extreme count is not reassurance against clotting; it requires acquired VWF assessment before aspirin.

Red flags requiring action

New focal neurology, chest pain, painful pale limb, abdominal pain or unusual-site thrombosis may be a clonal myeloproliferative presentation even when thrombocytosis was previously labelled reactive.
Recurrent epistaxis, gastrointestinal bleeding or postoperative oozing with platelets above approximately 1,000 × 10⁹/L suggests acquired von Willebrand syndrome and makes empirical aspirin hazardous.
Uraemia, severe liver disease, cardiopulmonary bypass or recent potent antiplatelet therapy can cause major platelet dysfunction despite a normal platelet count and routine coagulation tests.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line: repeat FBC and blood filmFirst stepFirst line
Why
Verify persistence and identify spurious counts or another myeloid phenotype.
Interpretation and limitations
Review haemoglobin, MCV and white-cell differential as well as platelet morphology. Fragments can be miscounted, while basophilia, leucoerythroblastosis or erythrocytosis redirects evaluation.
02
First-line: reactive-cause screenFirst line
Why
Find common reversible drivers before labelling a clonal disorder.
Interpretation and limitations
Use ferritin with transferrin saturation, CRP or ESR, renal and liver tests and phenotype-led infection, inflammatory and cancer assessment; ferritin may be falsely normal during inflammation.
03
Confirmatory clonal assessmentConfirmatory
Why
Detect an MPN when thrombocytosis remains unexplained or the phenotype is suspicious.
Interpretation and limitations
Test JAK2 V617F, CALR and MPL through the local pathway and BCR::ABL1 where CML remains possible. Bone-marrow architecture distinguishes ET, prefibrotic MF and masked PV.
04
VWF antigen and platelet-dependent activity
Why
Identify acquired von Willebrand syndrome during extreme thrombocytosis or unexplained mucosal bleeding.
Interpretation and limitations
Disproportionately reduced activity and loss of high-molecular-weight multimers support the diagnosis; discuss sampling and aspirin safety with a haemostasis laboratory.
05
Specialist platelet-function testing
Why
Characterise persistent clinically important dysfunction when the result changes treatment.
Interpretation and limitations
Light-transmission aggregometry or validated local assays require controlled sampling and medicine review. PFA closure time is affected by VWF, anaemia and count and is not a universal screen.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Laboratory or transient elevation

Platelet fragments, red-cell fragments or sampling error can cause a spurious automated count; repeat FBC and film confirm genuine persistent thrombocytosis.

Inherited platelet disorder

Lifelong bleeding, family history, childhood surgical haemorrhage and characteristic testing suggest congenital dysfunction rather than an acquired adult-onset defect.

Coagulation-factor deficiency

Haemophilia and acquired factor inhibitors more often cause deep tissue bleeding with an abnormal isolated APTT, unlike typical platelet-type mucosal bleeding.

Von Willebrand disease

Inherited VWD produces mucosal and procedural bleeding with abnormal VWF studies; history and repeat baseline testing separate it from count-related acquired VWF loss.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01New thrombocytosisConfirm and seek a driverFirst stepAn automated platelet count is at least 450 × 10⁹/L or unexpectedly rising.

1Repeat the FBC and inspect a film, comparing prior counts and the timing of acute illness or surgery.
2Assess iron status, inflammation, infection, bleeding, malignancy, splenectomy and renal or liver disease from history, examination and targeted tests.
3Treat a demonstrated secondary cause and document a repeat count; refer persistent unexplained or phenotypically concerning cases to haematology.

02Possible clonal diseaseIntegrate mutation and marrowThrombocytosis persists without explanation or occurs with thrombosis, splenomegaly or other abnormal counts.

1Obtain JAK2, CALR and MPL testing through the local pathway and test BCR::ABL1 when CML is plausible.
2Use marrow trephine and integrated clinical, molecular and morphological criteria to distinguish ET from prefibrotic MF and PV.
3Risk-stratify confirmed disease and choose antiplatelet or cytoreductive treatment in its disease-specific pathway.

03Bleeding at extreme countLook for acquired VWF lossMucosal or major bleeding accompanies marked thrombocytosis or aspirin is being considered at an extreme count.

1Withhold non-essential antiplatelet treatment, assess bleeding severity and send VWF antigen and activity with haemostasis advice.
2Control the source and use tranexamic acid, VWF replacement or other support only when suited to site, thrombosis risk and laboratory phenotype.
3Urgently reduce a pathogenic clonal platelet count with specialist cytoreduction; reserve plateletpheresis for selected life-threatening count-mediated events.

04Acquired dysfunctionCorrect mechanism before procedureClinically important bleeding or urgent surgery occurs with medicine exposure, uraemia or systemic disease despite adequate count.

1Define the bleeding site and urgency, check count and coagulation and review aspirin, P2Y12 inhibition, NSAIDs, renal failure, anaemia and paraprotein.
2Use mechanical haemostasis and correct reversible anaemia, uraemia or drug exposure without causing avoidable coronary or thrombotic harm.
3For severe bleeding, coordinate desmopressin, tranexamic acid, platelet transfusion or factor support with haematology, nephrology and the procedural team.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Produces a rapid temporary rise in endothelial VWF and can improve primary haemostasis during serious uraemic bleeding or an urgent procedure.

Desmopressin for selected uraemic bleeding

Give 0.3 micrograms/kg intravenously diluted and infused over 20–30 minutes shortly before the haemostatic challenge; use as a single monitored dose unless a haemostasis specialist explicitly directs repetition.

Restrict free water and monitor sodium because water retention can cause seizures; avoid repeated dosing because tachyphylaxis develops, and use caution in coronary disease, uncontrolled hypertension and severe fluid overload.

Stabilises formed clot and is useful for oral, nasal, dental and menstrual bleeding when pathological thrombosis is not the dominant risk.

Tranexamic acid

For suitable adult mucosal bleeding, a common regimen is 1 g orally three times daily for the shortest required course; use the exact local or product protocol and reduce the dose in renal impairment.

Avoid in active intravascular clotting and review macroscopic upper urinary-tract bleeding because obstructing clots may form. Dose accumulation in kidney failure increases adverse effects including seizures.

Supplies functional platelets when severe bleeding outweighs alloimmunisation and thrombosis risks, including selected recent antiplatelet exposure after specialist discussion.

Platelet transfusion

Give one adult therapeutic dose intravenously for major bleeding or an urgent high-risk procedure when platelet dysfunction is likely to be clinically relevant, then assess haemostasis and count before additional doses.

Do not transfuse for an abnormal function assay alone. Circulating antiplatelet medicine may inhibit donor platelets, while clonal thrombocytosis and recent coronary stenting require especially careful multidisciplinary balance.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Arterial and venous thrombosis

Stroke, myocardial infarction, limb ischaemia, DVT, pulmonary embolism and splanchnic thrombosis may complicate clonal thrombocytosis or its vascular risk factors.

Mucocutaneous haemorrhage

Epistaxis, gingival bleeding, menorrhagia, gastrointestinal loss and procedure-related oozing result from platelet dysfunction or acquired VWF deficiency.

Treatment-related bleeding

Aspirin, dual antiplatelet therapy and anticoagulation can convert modest platelet dysfunction into major bleeding, particularly with renal failure or acquired VWD.

Missed underlying disease

Persistent thrombocytosis may be the first sign of iron deficiency, inflammatory disease, occult cancer or a myeloproliferative neoplasm requiring separate follow-up.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Trend the platelet count after the presumed reactive driver is treated; failure to resolve should reopen clonal and occult-disease assessment.
Record thrombotic and bleeding symptoms rather than using the count as a surrogate for clinical risk, and give explicit urgent-return advice.
After desmopressin, monitor fluid intake, serum sodium and neurological symptoms, especially in older adults, kidney disease or repeated perioperative exposure.
During antiplatelet interruption, record the vascular indication, coronary-stent history, responsible specialist and a definite restart decision.
For confirmed MPN, monitor FBC, vascular risk, treatment toxicity, splenic or systemic symptoms and acquired VWF status when counts or bleeding change.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Count is not function

A normal platelet count can coexist with severe acquired dysfunction, while an extreme count may paradoxically reduce effective VWF-dependent adhesion.

Reactive is a diagnosis with evidence

A plausible inflammatory or iron-deficient context should improve with treatment; persistence requires reassessment rather than an indefinite secondary label.

Aspirin can reverse the lesson

It may relieve clonal microvascular symptoms, yet can materially worsen active mucosal bleeding or count-related acquired VWD.

Uraemia has several levers

Dialysis adequacy, anaemia correction, medicine review and local haemostasis matter alongside any short-lived response to desmopressin.

Functional tests are fragile

Pre-analytical conditions, anaemia, VWF level, platelet count and recent medicines can change results, so specialist interpretation is essential.

11Common pitfallsFrequent interpretation and management errors.

01
Treating every raised platelet count with aspirin.
02
Calling thrombocytosis reactive without documenting resolution.
03
Ignoring iron deficiency because haemoglobin is initially normal.
04
Assuming normal PT and APTT exclude platelet dysfunction.
05
Giving aspirin during bleeding from acquired VWF loss.
06
Stopping dual antiplatelet therapy after coronary stenting without cardiology agreement.